

Start-up Companies or Pre-Company Projects Funded by Georgia Research Alliance (March 2005-January 2022)

				Total	Active	Inactive				
				Total # Awards	333	246	87			
				Total # Companies/Projects	138	89	49			
				Total Funding	\$15,090,548					
No.	Company/Project	Technology Type	PI	Department	Phase	Award Date	Amount	Purpose	Project / Active?	Company Total
1	5M Biomed	diagnostics	Hui Mao	Radiology	IA	5/13/20	\$29,780	develop an in vitro diagnostic for diagnosis and monitoring Alzheimer's disease (AD) and AD related dementias (ADRD) further optimize the technology to achieve the necessary sensitivity and specificity to targeted biomarkers and evaluate performance	Y	\$56,560
1	5M Biomed	diagnostics	Hui Mao	Radiology	IB	8/4/21	\$26,780	independent data validation	Y	
2	Abby Med, LLC	drug discovery	Jack Arbiser	Dermatology	IA	3/6/14	\$34,000	formulation and GMP studies / preclinical safety and efficacy testing / IND readiness	Y	\$235,225
2	Abby Med, LLC	drug discovery	Jack Arbiser / Ravi Bellamkond	Dermatology / Biomedical Eng	IB	10/23/14	\$110,000	production, pre-clinical animal model validation	Y	
2	Abby Med, LLC	drug discovery	Jack Arbiser/Ravi Bellamkonda	Dermatology/ Biomedical Eng	IIA	10/11/17	\$40,600	IND enabling studies	Y	
2	Abby Med, LLC	drug discovery	Jack Arbiser	Dermatology	IIB	3/18/19	\$50,625	formulation, GMP stability studies	Y	
3	Accutis	proteasome inhibitor for skin aging, rosacea a	Jack Arbiser	Dermatology	IA	4/5/12	\$25,000	IND enabling studies	Y	\$409,700
3	Accutis	proteasome inhibitor for skin aging, rosacea a	Jack Arbiser	Dermatology	IB	1/7/13	\$25,000	IND-enabling studies	Y	
3	Accutis	proteasome inhibitor for skin aging, rosacea a	Jack Arbiser	Dermatology	IIA	9/26/13	\$50,000	formulation, GMP stability studies	Y	
3	Accutis	proteasome inhibitor for skin aging, rosacea a	Jack Arbiser	Dermatology	IIB	5/28/14	\$59,700	IND enabling studies	Y	
3	Accutis	proteasome inhibitor for skin aging, rosacea a	Jack Arbiser	Dermatology	IIIA	6/22/15	\$150,000	toxicology studies	Y	
3	Accutis	proteasome inhibitor for skin aging, rosacea a	Jack Arbiser	Dermatology	IIIB	11/18/16	\$100,000	toxicology studies	Y	
4	AgriThera	drug development	Dennis Liotta	Chemistry	IA	7/22/20	\$25,000	synthesize a library of new CBD prodrugs, perform in vitro characterization, and obtain in vivo data	Y	\$50,000
4	AgriThera	drug development	Dennis Liotta	Chemistry	IB	11/8/21	\$25,000	exploring the impact of transporter substrate groups on brain penetration and overall tissue distribution	Y	
5	AKESOgen	biomarker profiling & services	Mark Bouzyk	Human Genetics	IIA	1/3/11	\$50,000	facility remodeling	Y	\$350,000
5	AKESOgen	biomarker profiling & services	Mark Bouzyk	Human Genetics	IIB	2/21/11	\$50,000	company infrastructure	Y	
5	AKESOgen	biomarker profiling & services	Mark Bouzyk	Human Genetics	IIIA	10/7/11	\$100,000	key instruments	Y	
5	AKESOgen	biomarker profiling & services	Mark Bouzyk	Human Genetics	IIIB	1/23/12	\$150,000	illumina iScan, Kingfisher, AB7900	Y	
6	AlphaStem, LLC	cardiovascular stem cell therapy	Young Sup Yoon	Cardiology	IA	7/20/12	\$4,000	business model	Y	\$86,700
6	AlphaStem, LLC	cardiovascular stem cell therapy	Young Sup Yoon	Cardiology	IB	9/4/2014	\$82,700	prototype testing and business development	Y	
7	Alternative Cellular Therapeutics	oncology Immunotherapy	H. Trent Spencer	Pediatrics	IB	12/22/14	\$37,000	efficacy studies in cell and animal models of neuroblastoma	Y	\$68,600
7	Alternative Cellular Therapeutics	cell therapy	H. Trent Spencer	Pediatrics	IA	3/6/14	\$31,600.00	in vitro POP studies	Y	
8	AngioCloud	Imaging software	Fran Tong & Alessandro Venezi	Radiology; Math & Comp Sci	IA	3/6/14	\$54,400	prototyping	Y	\$188,657
8	AngioCloud	Imaging software	Fran Tong & Alessandro Venezi	Radiology; Mathematics	IB	3/2/20	\$34,257	UI development	Y	
8	AngioCloud	Imaging software	Fran Tong & Alessandro Venezi	Radiology; Mathematics	IIA	3/5/21	\$66,230	enhance the platform features and functions to support FDA approval and commercial readiness	Y	
8	AngioCloud	Imaging software	Fran Tong & Alessandro Venezi	Radiology; Mathematics	IIB	6/30/21	\$33,770	complete the milestones necessary to gain FDA 510K approval	Y	
9	Artificial Platelets	drug discovery	Wilbur Lam	Pediatrics, Hematology and On	IA	7/17/18	\$8,000	market research	Y	\$40,000
9	Artificial Platelets	drug discovery	Wilbur Lam	Pediatrics, Hematology and On	IB	4/12/19	\$32,000	market research, antibody production	Y	
10	Behavioral Science Technologies	web-based software	Laura Salazar	School of Public Health	IA	9/26/13	\$22,800.00	business model	Y	\$22,800.00
11	Bio Pace (formerly Biological Pacemaker)	drug discovery	Hee Cheol Cho	Biomedical Engineering	IA	6/27/17	\$30,300	synthesis, in vitro validation	Y	\$189,974
11	Bio Pace (formerly Biological Pacemaker)	drug discovery	Hee Cheol Cho	Biomedical Engineering	IB	4/11/18	\$54,500	large scale synthesis, preclinical studies	Y	
11	Bio Pace (formerly Biological Pacemaker)	drug discovery	Hee Cheol Cho	Biomedical Engineering	IIA/IIB	7/31/18	\$105,174	validation studies	Y	
12	BioData Consortium	software for medical imaging	Hari Trivedi	Radiology	IA	7/10/19	\$25,000	framework development & prototyping	Y	\$100,000
12	BioData Consortium	software for medical imaging	Hari Trivedi	Radiology	IB	1/21/20	\$25,000	algorithm refinement & testing	Y	
12	BioData Consortium	software for medical imaging	Hari Trivedi	Radiology	IIA	12/15/20	\$50,000	optimize and productize software for licensing	Y	
13	Braegen Pharmaceuticals	drug discovery	Keqiang Ye	Pathology	BIO/Plan	7/16/07	\$25,000	business plan	Y	\$25,000
14	Cambium Medical Technologies	blood products	Ian Copland, Jaques Galipeau,	Hematology/Oncology, Pathol	IA	10/10/11	\$25,000	product comparison	Y	\$110,000
14	Cambium Medical Technologies	blood products	Ian Copland, Jaques Galipeau,	Hematology/Oncology, Pathol	IB	4/5/12	\$25,000	pre-clinical testing	Y	
14	Cambium Medical Technologies	blood products	Ian Copland, Jaques Galipeau,	Hematology/Oncology, Pathol	IC	5/28/14	\$60,000	GLP in vivo toxicology testing	Y	
15	Cambium Oncology	drug development	Edmund K. Waller	Hematology and Medical Oncr	IA	4/28/20	\$28,200	pre-clinical testing of the lead VIP antagonist(s) utilize a CRO to confirm data previously generated in the	Y	\$77,650
15	Cambium Oncology	drug development	Edmund K. Waller	Hematology and Medical Oncr	IB	4/26/21	\$49,450	academic lab	Y	
16	Camerad Technologies	medical device	Srini Tridandapani	Radiology	IA	7/20/12	\$3,000	market study	Y	\$50,000

16	Camerad Technologies	medical device	Srini Tridandapani	Radiology	IB	10/11/12	\$22,000	prototyping	Y	
16	Camerad Technologies	medical device	Srini Tridandapani	Radiology	IC	9/26/13	\$25,000	6 products for clinical testing	Y	
17	Centizyme	drug discovery	Khalid Salaita/Chrerry Wongtr	Chemistry/Pulmonary	IA1	11/13/17	\$10,000	dose response studies	Y	\$55,200
17	Centizyme	drug discovery	Khalid Salaita/Chrerry Wongtr	Chemistry/Pulmonary	IA2	1/18/18	\$35,200	dose response studies	Y	
17	Centizyme	drug discovery	Khalid Salaita/Chrerry Wongtr	Chemistry/Pulmonary	IA3	8/15/18	\$10,000	dose response studies	Y	
18	Clearside Biomedical	ophthalmic therapeutics	Henry Edelhauser	Eye Center	IA (to GT)	8/24/11	\$25,000	prototyping	Y	\$285,000
18	Clearside Biomedical	ophthalmic therapeutics	Henry Edelhauser	Eye Center	BIO/Plan	10/12/11	\$10,000	business development	Y	
18	Clearside Biomedical	ophthalmic therapeutics	Henry Edelhauser	Eye Center	IIA	4/5/12	\$50,000	product development	Y	
18	Clearside Biomedical	ophthalmic therapeutics	Henry Edelhauser	Eye Center	IIB	7/20/12	\$50,000		Y	
18	Clearside Biomedical	ophthalmic therapeutics	Henry Edelhauser	Eye Center	IIIA	11/9/12	\$150,000		Y	
19	CloudTags	mobile application	Stephen P Stuk	Goizueta Business School	IA	7/7/14	\$15,000	software development, consumer implementation increased product selection, consumer informatics, and	Y	\$90,000
19	CloudTags	mobile application	Stephen P Stuk	Goizueta Business School	IIA	1/9/15	\$75,000	product features	Y	
20	Cognition Medical	medical device	Jonathan Grossberg	Neurosurgery	IIA	2/1/18	\$84,000	prototyping and testing	Y	\$150,000
20	Cognition Medical	medical device	Jonathan Grossberg	Neurosurgery	IIB	2/19/19	\$66,000	prototyping and testing	Y	
21	CorAmi (formerly Levit Device)	medical device	Rebecca Levit	Cardiology	IA	5/21/15	\$11,788	develop amiodarone-releasing gel	Y	\$191,690
21	CorAmi (formerly Levit Device)	medical device	Rebecca Levit	Cardiology	IB	1/14/16	\$58,177	evaluation in small animal model	Y	
21	CorAmi (formerly Levit Device)	medical device	Rebecca Levit	Cardiology	IIA	4/25/17	\$29,929	evaluation in pig model	Y	
21	CorAmi (formerly Levit Device)	medical device	Rebecca Levit	Cardiology	IIB	10/3/17	\$41,930	<i>in vitro</i> optimization, small animal testing (amiodarone)	Y	
22	Covanos (formerly DASH or C-Heart)	medical device	Habib Samady	Cardiology	IB	12/8/16	\$49,866	coding, design, validation, business strategy	Y	
22	Covanos (formerly DASH or C-Heart)	medical device	Habib Samady	Cardiology	IA	12/18/15	\$80,455		Y	\$234,359
22	Covanos (formerly DASH or C-Heart)	medical device	Habib Samady	Cardiology	IC	6/28/17	\$74,952	code refinement, consulting	Y	
22	Covanos (formerly DASH or C-Heart)	medical device	Habib Samady	Cardiology	ID	11/13/17	\$38,952	prototype SW, test with patient data	Y	
22	Covanos (formerly DASH or C-Heart)	medical device	Habib Samady	Cardiology	IE	3/29/18	\$40,000	prototype validation, testing	Y	
23	Diasyst	software for diabetes care	Lawrence Philips	Endocrinology	IA	3/31/16	\$50,000	market validation, SW mockup	Y	\$200,000
23	Diasyst	software for diabetes care	Lawrence Philips	Endocrinology	IB	6/30/16	\$50,000	patient Android app, algorithm development	Y	
23	Diasyst	software for diabetes care	Lawrence Philips	Endocrinology	IIA	3/26/17	\$50,000	510(k) submission, Emory Cerner integration	Y	
23	Diasyst	software for diabetes care	Lawrence Philips	Endocrinology	IIB	1/9/19	\$50,000	software development proof of concept that product will improve survival rates of patients with relapsed and refractory (r/r) lymphoid	Y	
24	DiuTinus	T cell therapies	Rafick Pierre Sekaly	Pathology	IA	4/19/21	\$27,800	malignancies	Y	\$27,800
25	Dr. NozeBest (formerly BeeClear)	medical device	Steven Goudy	Otolaryngology	IA	4/27/16	\$22,500	design, testing, consulting	Y	\$151,000
25	Dr. NozeBest (formerly BeeClear)	medical device	Steven Goudy	Otolaryngology	IB	3/8/17	\$8,500	prototyping, market analysis, business plan	Y	
25	Dr. NozeBest (formerly BeeClear)	medical device	Steven Goudy	Otolaryngology	IC	6/27/18	\$25,000	prototype refining	Y	
25	Dr. NozeBest (formerly BeeClear)	medical device	Steven Goudy	Otolaryngology	IIA	1/9/19	\$40,000	prototype validation, testing	Y	
25	Dr. NozeBest (formerly BeeClear)	medical device	Steven Goudy	Otolaryngology	IIB	5/12/20	\$55,000	final prototype production and electronic testing	Y	
26	DRIVE Influenza	drug discovery	Alexander Kolyholav	EIDD	IA	4/11/18	\$25,000	pre-clinical testing	Y	\$30,000
26	DRIVE Influenza	drug discovery	Alexander Kolyholav	EIDD	IB	9/4/18	\$5,000	pre-clinical efficacy testing	Y	
27	DRIVE Influenza II	drug development	Gregory Bluemling	EIDD	IA	4/6/20	\$25,000	PK, distribution, and toxicity studies	Y	\$25,000
28	DRIVE Rhinovirus	drug development	Gregory Bluemling	EIDD	IA	9/16/19	\$25,000	half-life studies	Y	\$25,000
29	Drusco	drug discovery	Abel De La Rosa	Emory Institute for Drug Deve	IA	9/18/17	\$42,500	pre-formulation, cytotoxicity testing	Y	\$77,000
29	Drusco	drug discovery	Abel De La Rosa	Emory Institute for Drug Deve	IB	6/5/18	\$34,500	production, AMES, toxicity, etc.	Y	
30	Early Detection of Alzheimer's Disease	diagnostic	Nicholas Seyfried/Alan Levey	Neurology	IA	7/31/18	\$24,700	screening, peptide synthesis	Y	\$24,700
31	E-CARE	Natural Language Processing (NLP) tool	Elaine Fisher	Nursing	IA	8/26/20	\$16,226	improve input to and accuracy of the model	Y	\$50,038
31	E-CARE	Natural Language Processing (NLP) tool	Elaine Fisher	Nursing	IB	6/29/21	\$33,812	development and deployment of an HR-recruiter facing portal	Y	
32	EMRGE	medical device	Felmont Eaves	Surgery	IA	9/26/13	\$63,500	prototyping	Y	\$457,300
32	EMRGE	medical device	Felmont Eaves	Surgery	IB	7/14/14	\$93,800	GMP, animal testing, market testing	Y	
32	EMRGE	medical device	Felmont Eaves	Surgery	IIA	1/28/16	\$100,000	prototyping & small scale manufacturing	Y	
32	EMRGE	medical device	Felmont Eaves	Surgery	IIB	4/18/17	\$50,000	design validation and manufacturing marketing & business plan, manufacturing for commercial	Y	
32	EMRGE	medical device	Felmont Eaves	Surgery	IIIA	1/24/18	\$150,000	launch	Y	
33	EmTheraPro	diagnostics	Nicholas T. Seyfried and Allan I	Neurology	IIA	6/21/21	\$50,505	further develop operations to successfully deliver on first MVP analytical assay development; aerosol development; bio-	Y	\$50,505
34	Eric Sorscher Special Award - PDE4 Inhi	drug development	Eric Scorscher	Pediatrics	IA	8/12/20	\$77,500	analytical assay development	Y	\$77,500
35	Expression Therapeutics	drug discovery	John Lollar	Pediatrics	Industry Partn	3/30/07	\$100,000	animal studies	Y	\$100,000
36	Extended Wear Carrier for Liquid Deod	medical device	Charlene Toney, Cynthia Timm	Emory Healthcare	IA	7/20/12	\$25,000	prototyping	Y	\$25,000
37	Focused Cryo	medical device	David Prologo	Radiology	IIA1	12/19/19	\$10,000	IRB & FDA approval, patient recruitment	Y	\$198,300

37	Focused Cryo	medical device	David Prologo	Radiology	IIA2	2/10/20	\$68,300	data acquisition, safety monitoring	Y	
37	Focused Cryo	medical device	David Prologo	Radiology	IIB	2/10/20	\$70,000	data analysis	Y	
37	Focused Cryo	medical device	David Prologo	Radiology	IIC	8/25/20	\$50,000	develop, test, and validate the sensor fusion algorithm collect clinical comparison data to develop automated algorithms to detect sleep-disordered breathing and sleep stages	Y	
38	Huxley Medical	medical device/diagnostics	Surina Sharma	School of Medicine, Emory Sle	IIA	12/2/21	\$81,769	design and prototype our device and obtain user feedback on the various prototype designs	Y	\$81,769
39	IACS	device	Adam Klein	Otolaryngology	IA	10/28/20	\$15,000	perform final validation on the MVP; submit testing data to the FDA for an EUA	Y	\$30,000
39	IACS	device	Adam Klein	Otolaryngology	IB	8/30/21	\$15,000	pig studies to confirm mechanism of action	Y	
40	Iconic Therapeutics	drug development	Timothy Olsen	Eye Center	IIA	8/31/09	\$48,000	\$50,000	Y	\$348,000
40	Iconic Therapeutics	drug development	Timothy Olsen	Eye Center	IIB	1/12/10	\$50,000	toxicity studies	Y	
40	Iconic Therapeutics	drug development	Timothy Olsen	Eye Center	IIIA	4/9/10	\$150,000		Y	
40	Iconic Therapeutics	drug development	Timothy Olsen	Eye Center	IIIB	7/12/10	\$100,000		Y	
41	Inhibikase	drug discovery	Daniel Kalman	Pathology	IA	9/25/08	\$25,000	technical & market assessment	Y	\$455,600
41	Inhibikase	drug discovery	Daniel Kalman	Pathology	IB	11/20/08	\$25,000	salary support	Y	
41	Inhibikase	drug discovery	Daniel Kalman	Pathology	IC	11/20/08	\$55,600	raising capital	Y	
41	Inhibikase	drug discovery	Daniel Kalman	Pathology	IIA	8/31/09	\$50,000	cell-based antiviral efficacy	Y	
41	Inhibikase	drug discovery	Daniel Kalman	Pathology	IIB	10/26/09	\$50,000	IKT-401 antiviral efficacy	Y	
41	Inhibikase	drug discovery	Daniel Kalman	Pathology	IIIA	7/16/10	\$150,000	in vivo dose response	Y	
41	Inhibikase	drug discovery	Daniel Kalman	Pathology	IIIB	9/23/11	\$100,000	efficacy in animal model	Y	\$350,000
42	InVasc	drug development	Bobby Khan	Cardiology	IIA	7/29/09	\$50,000	lead candidate formulation	Y	
42	InVasc	drug development	Bobby Khan	Cardiology	IIB	10/26/09	\$50,000	IND filing	Y	
42	InVasc	drug development	Bobby Khan	Cardiology	IIIA	12/16/09	\$150,000	IND filing	Y	
42	InVasc	drug development	Bobby Khan	Cardiology	IIIB	3/23/10	\$100,000	develop the first generation of an automated cell culture technology	Y	\$29,000
43	InvenTech Solutions	device	Vahid Serpooshan	Biomedical Engineering	IA	7/24/20	\$29,000	business plan	Y	\$50,000
44	Katharos	drug discovery	Erwin Van Meir	Neurosurgery	BIO/Plan	7/16/07	\$25,000	ADME & safety evaluation	Y	
44	Katharos	drug discovery	Erwin Van Meir	Neurosurgery	IA	4/4/08	\$25,000	pre-clinical <i>in vitro</i> & <i>in vivo</i> studies	Y	\$100,000
45	Kodikaz	gene therapy	Leon Bernal-Mizrachi	Hematology/Medical Oncolog	IIA	7/10/19	\$50,000	explore the development of other zip-code candidates in melanoma	Y	
45	Kodikaz	gene therapy	Leon Bernal-Mizrachi	Hematology/Medical Oncolog	IIB	9/28/20	\$50,000	develop small molecule KRAS(G12V)-targeting anticancer agents	Y	\$30,000
46	KRAS	drug development	Haian Fu	Pharmacology & Chemical Bio	IA	1/29/21	\$30,000	preclinical studies, PK testing	Y	\$75,460
47	PreciseBio	research tool/drug discovery	Adam Marcus	Hematology & Oncology	IA	5/24/18	\$35,460	pre-clinical testing and mechanism of action of AX-7	Y	
47	Leader Bio formerly Precise Biotech	research tool/drug discovery	Adam Marcus	Hematology and Medical Oncr	IB	12/10/20	\$40,000	prototyping	Y	\$108,806
48	Lucid	drug discovery	George Painter	DRIVE	IA	6/27/18	\$23,883	testing, validation	Y	
48	Lucid	drug discovery	George Painter	DRIVE	IB	2/19/19	\$26,400	dose response, small scale manufacturing	Y	
48	Lucid	drug discovery	George Painter	DRIVE	IIA	7/10/19	\$58,523	market analysis	Y	\$50,000
49	Macular Regeneration	medical device	Timothy Olsen	Eye Center	IA	2/27/09	\$25,000	consulting, design	Y	\$182,640
49	Macular Regeneration	medical device	Timothy Olsen	Eye Center	IB	7/9/09	\$25,000	prototyping and software development	Y	
50	MamaliBra (formerly Tumaas or Breast	medical device	Andrea Joyner	Gynecology & Obstetrics	IA	8/23/17	\$25,000	prototyping, regulatory compliance	Y	
50	MamaliBra (formerly Tumaas or Breast	medical device	Andrea Joyner	Gynecology & Obstetrics	IB	2/1/18	\$30,000	design iteration & implementation	Y	
50	MamaliBra (formerly Tumaas or Breast	medical device	Andrea Joyner	Gynecology & Obstetrics	IIA	3/18/19	\$77,640	proof of concept	Y	\$106,925
50	MamaliBra (formerly Tumaas or Breast	medical device	Andrea Joyner	Gynecology & Obstetrics	IIB	11/13/19	\$50,000	prototype refinement	Y	
51	MapHabit	software	Camille Vaughan	Medicine-Geriatrics	IA	10/16/18	\$58,490	vaccine evaluation	Y	\$15,000
51	MapHabit	software	Camille Vaughan	Medicine-Geriatrics	IB	1/9/19	\$48,435	antibody production	Y	\$107,543
52	Metaclipse (formerly Vaccine Project)	melanoma vaccine	Periasamy Selvaraj	Pathology	Phase 0	3/13/08	\$15,000	business plan	Y	
53	Metaclipse (formerly Vaccine Project)	cell-based therapy	Periasamy Selvaraj	Pathology	IA	11/11/10	\$25,000	IND enabling studies	Y	
53	Metaclipse (formerly Vaccine Project)	cell-based therapy	Periasamy Selvaraj	Pathology	IB	11/8/11	\$25,000		Y	
53	Metaclipse (formerly Vaccine Project)	cell-based therapy	Periasamy Selvaraj	Pathology	IIA	4/20/12	\$42.50		Y	
53	Metaclipse (formerly Vaccine Project)	cell-based therapy	Periasamy Selvaraj	Pathology	IIB	7/20/12	\$57,500		Y	
54	Microbial Medical (formerly Microbial I	medical device	W. Robert Taylor & Mark Goo	Cardiology, Radiology	IA	4/10/14	\$45,613.00	in vitro cytotoxicity testing	Y	\$315,613.00
54	Microbial Medical (formerly Microbial I	medical device	W. Robert Taylor & Mark Goo	Cardiology, Radiology	IB	2/17/15	\$95,000.00	synthesis & toxicology studies	Y	
54	Microbial Medical (formerly Microbial I	medical device	W. Robert Taylor & Mark Goo	Cardiology, Radiology	IIA	12/8/15	\$100,000.00	pre-clinical efficacy studies	Y	
54	Microbial Medical (formerly Microbial I	medical device	W. Robert Taylor & Mark Goo	Cardiology, Radiology	IIB	10/3/16	\$75,000.00	GLP toxicology studies & consulting	Y	
55	MicroBplex	diagnostics	Frances Eun-Hyung Lee	Pulmonology	IA	7/20/12	\$25,000	prototyping	Y	\$248,679
55	MicroBplex	diagnostics	Frances Eun-Hyung Lee	Pulmonology	IB	5/28/14	\$73,000	test kits, business plan	Y	
55	MicroBplex	diagnostics	Frances Eun-Hyung Lee	Pulmonology	IIA	6/30/16	\$100,000	consultants (market analysis) & supplies	Y	

55	MicroBplex	diagnostics	Frances Eun-Hyung Lee	Pulmonology	IIB	9/8/17	\$50,679	test on early stage Lyme disease subjects	Y	
56	Migra Therapeutics	drug delivery	Lily Yang	Surgery	IA	3/29/18	\$35,786	protein & nanoparticle production	Y	\$187,487
56	Migra Therapeutics	drug delivery	Lily Yang	Surgery	IB	1/22/19	\$51,701	preclinical studies	Y	
56	Migra Therapeutics	drug delivery	Lily Yang	Surgery	IIA	8/5/20	\$50,000	preclinical testing for novel drug delivery system	Y	
56	Migra Therapeutics	drug delivery	Lily Yang	Surgery	IIB	1/21/22	\$50,000	IND-enabling studies	Y	
57	NanoV Therapeutics	drug discovery	Jie Song/Craig Hill	Chemistry	IA	7/27/17	\$24,837.50	efficacy, toxicity testing	Y	\$24,837.50
58	NatGlycan	research tool/method	David Smith	Biochemistry	IA	12/8/16	\$25,000	optimization, characterization, activity testing	Y	\$50,000
58	NatGlycan	research tool/method	David Smith	Biochemistry	IB	9/27/17	\$25,000	optimize porcine heparin production protocol	Y	
59	Neovaccine Strategies	drug discovery	Joanna Goldberg	Pediatrics	IA	1/9/19	\$50,000	protein purification, preclinical studies	Y	\$74,665
59	Neovaccine Strategies	drug discovery	Joanna Goldberg	Pediatrics	IB	3/2/20	\$24,665	patient sampling & ELISA testing	Y	
60	NephroDI (formerly Novel AMPK Activa drug discovery		Janet Klein/Jeff Sands	Medicine/Renal	IA	11/8/16	\$24,181	dose response studies	Y	\$109,181
60	NephroDI (formerly Novel AMPK Activa drug discovery		Janet Klein/Jeff Sands	Medicine/Renal	IB	6/6/17	\$50,000	efficacy studies	Y	
60	NephroDI (formerly Novel AMPK Activa drug discovery		Janet Klein/Jeff Sands	Medicine/Renal	IC	6/5/18	\$35,000	oral formulation, PK studies	Y	
								regulatory filing; biocompatibility testing; bench usability; large		
61	NeuBulk		Niall Galloway	Urology	IA	10/19/21	\$35,000	animal study	Y	\$35,000
62	NeurOp	drug discovery	Raymond Dingleline	Pharmacology	IIA	3/25/05	\$50,000	ADMET	Y	\$425,000
62	NeurOp	drug discovery	Raymond Dingleline	Pharmacology	IIB	8/15/05	\$50,000	other pre-clinical studies	Y	
62	NeurOp	drug discovery	Raymond Dingleline	Pharmacology	special award	9/15/06	\$25,000	patent support	Y	
62	NeurOp	drug discovery	Raymond Dingleline	Pharmacology	IIC	4/6/09	\$50,000	bridging funding prior to partnership	Y	
62	NeurOp	drug discovery	Raymond Dingleline	Pharmacology	IIIA	11/17/10	\$150,000		Y	
62	NeurOp	drug discovery	Raymond Dingleline	Pharmacology	IIIB	10/7/11	\$100,000	pre-clinical studies	Y	
63	NeuroTrack	diagnostic software	Stuart Zola, Elizabeth Buffalo, E Yerkas, Emory College		IA	8/22/11	\$25,000	clinical validation	Y	\$50,000
63	NeuroTrack	diagnostic software	Stuart Zola, Elizabeth Buffalo, E Yerkas, Emory College		IB	8/21/12	\$25,000	partnership development	Y	
64	NovAb	therapeutic antibodies for multiple myeloma	Max Cooper and Brantley Herr Pathology		IA	4/5/12	\$25,000	initial product development	Y	\$350,000
64	NovAb	therapeutic antibodies for multiple myeloma	Max Cooper and Brantley Herr Pathology		IB	12/18/12	\$25,000	production and marketing marketing	Y	
64	NovAb	therapeutic antibodies for multiple myeloma	Max Cooper and Brantley Herr Pathology		IC	5/28/14	\$50,000	humanization	Y	
64	NovAb	oncology immunotherapy	Max Cooper and Brantley Herr Pathology		IIA	12/22/14	\$150,000	licensing and target validation	Y	
64	NovAb	oncology immunotherapy	Max Cooper and Brantley Herr Pathology		IIB	4/27/16	\$100,000	salary and supplies for pre-clinical work	Y	
65	Nyra Medical (formerly Mitra Plug)	medical device	Muralidhar Padala	Cardiothoracic Surgery	BIO/Plan	10/10/11	\$10,000	business plan	Y	\$239,024
65	Nyra Medical (formerly Mitra Plug)	medical device	Muralidhar Padala	Cardiothoracic Surgery	IA	1/26/12	\$25,000	prototyping	Y	
65	Nyra Medical (formerly Mitra Plug)	medical device	Muralidhar Padala	Cardiothoracic Surgery	IB	7/14/14	\$52,300	efficacy in animal models	Y	
65	Nyra Medical (formerly Mitra Plug)	medical device	Muralidhar Padala	Cardiothoracic Surgery	IC	4/27/16	\$20,000	animal safety & efficacy studies	Y	
65	Nyra Medical (formerly Mitra Plug)	medical device	Muralidhar Padala	Cardiothoracic Surgery	IIA	9/26/16	\$74,939	further prototyping & animal studies	Y	
65	Nyra Medical (formerly Mitra Plug)	medical device	Muralidhar Padala	Cardiothoracic Surgery	IIB	1/21/20	\$56,785	control file design, process development	Y	
66	OncoSpherix (formerly Van Meir Projec drug discovery		Erwin Van Meir	Neurosurgery, Winship	IA	2/12/18	\$22,432	xenograft studies, consulting	Y	\$217,415
66	OncoSpherix (formerly Van Meir Projec drug discovery		Erwin Van Meir	Neurosurgery, Winship	IB	6/27/18	\$53,397	xenograft, syngery, toxicity studies	Y	
66	OncoSpherix (formerly Van Meir Projec drug discovery		Erwin Van Meir	Neurosurgery, Winship	IC	4/12/19	\$41,586	preclinical studies, lead optimization	Y	
								preclinical testing of lead compound, 64B; improve the		
66	OncoSpherix (formerly Van Meir Projec drug discovery		Erwin Van Meir	Neurosurgery, Winship	IIA	2/2/21	\$53,334	synthetic method for 64B	Y	
								compare and combine 64B with sunitinib and selumetinib for		
66	OncoSpherix (formerly Van Meir Projec drug discovery		Erwin Van Meir	Neurosurgery, Winship	IIB	8/2/21	\$46,666	treatment of UM in mice; scale-up of 64B	Y	
								develop AI models based on various datasets; obtain clinical		
67	Oral Cavity & Oropharynx Cancer Scree	cancer screening	William Stokes	Radiation Oncology	IA	10/3/21	\$24,000	samples on 20 OC/OPC patients and 5 controls	Y	\$24,000
68	OrthoApp	software	Scott Boden	Orthopedics	IA	2/1/18	\$39,500	market research, UX prototype	Y	\$39,500
69	PDXScan	software	Daniel Huddleston	Neurology	IA	5/24/18	\$17,500	algorithm optimization	Y	\$50,000
								complete cloud-based, automated image processing and		
69	PDXScan	software	Daniel Huddleston	Neurology	IB	7/24/20	\$32,500	integration of the image processing pipeline	Y	
70	PhytoTEK	drug discovery	Cassandra Quave	Emory College	IA	7/20/12	\$25,000	IND enabling-studies	Y	\$50,000
70	PhytoTEK	drug discovery	Cassandra Quave	Emory College	IB	9/26/13	\$25,000	formulation & optimization	Y	
71	PNP Therapeutics	drug development	Eric Sorscher/Turang Behbaha	Pediatrics, GME	IA	7/31/18	\$50,000	pre-clinical studies	Y	\$150,000
71	PNP Therapeutics	drug development	Eric Sorscher/Jeong Hong	Pediatrics	IIA	11/22/19	\$50,000	pre-clinical <i>in vivo</i> studies	Y	
								advance PNP technology to clinical testing for patients with		
71	PNP Therapeutics	drug development	Eric Sorscher/Jeong Hong	Pediatrics	IIB	12/15/20	\$50,000	otherwise refractory carcinomas of the breast	Y	
72	Proxime (formerly μTED)	medical device	Wilbur Lam	Pediatrics	IA	2/1/18	\$27,000	finalize clinical scale prototype	Y	\$67,087.50
72	Proxime (formerly μTED)	medical device	Wilbur Lam	Pediatrics	IB	8/26/19	\$40,088	user engagement, regulatory documentation	Y	
73	Pyrefin (formerly EP2 Antagonists)	drug development	Ray Dingleline	Pharmacology	IA	2/19/19	\$48,054	toxicity, DMPK studies	Y	\$154,315
73	Pyrefin (formerly EP2 Antagonists)	drug development	Ray Dingleline	Pharmacology	IB	8/13/19	\$52,585	regulatory/pre-IND documentation	Y	

							optimize an oral formulation of PY1177 for dose range finding			
73	Pyrefin (formerly EP2 Antagonists)	drug development	Ray Dingleline	Pharmacology	IIA	8/2/21	\$53,676	studies in vivo; develop an ex vivo blood biomarker	Y	
74	QUE Oncology	drug development	Dennis Liotta	Chemistry	IIB	7/14/14	\$98,900	clinical evaluation (Phase IB)	Y	\$517,900
74	QUE Oncology	drug development	Dennis Liotta	Chemistry	IA	10/11/12	\$25,000	lead indication of first drug candidate	Y	
74	QUE Oncology	drug development	Dennis Liotta	Chemistry	IB	2/19/13	\$25,000	plans for IND submission	Y	
74	QUE Oncology	drug development	Dennis Liotta	Chemistry	IIA	9/26/13	\$119,000	IND-Q122 hot flashes study	Y	
74	QUE Oncology	drug development	Dennis Liotta	Chemistry	IIIA	7/20/15	\$150,000		Y	
74	QUE Oncology	drug development	Dennis Liotta	Chemistry	IIIB	11/12/15	\$100,000		Y	
75	Rare Cystic Fibrosis Mutation	drug development	Eric Sorscher/?	Pediatrics/EIDD	IA	4/9/20	\$50,000	compound stability studies	Y	\$100,000
75	Rare Cystic Fibrosis Mutation	drug development	Eric Sorscher and Andras Rab	Pediatrics/EIDD	IB	3/24/21	\$50,000	pharmacokinetic profiles of HDCF 104	Y	
76	Repredix	software	Amith Shah/Gari Clifford	Epidemiology/BMI	IA	7/15/16	\$44,000	coding, data analysis	Y	\$105,000
76	Repredix	software	Amith Shah/Gari Clifford	Epidemiology/BMI	IB	7/27/17	\$25,000	data collection, algorithm refinement	Y	
76	Repredix	software	Amith Shah/Gari Clifford	Epidemiology/BMI	IC	3/29/18	\$36,000	data collection, algorithm refinement	Y	
77	ResonanceDx	diagnostics	Carlos Moreno	Pathology & Laboratory Med	IA	8/10/17	\$28,000	manufacturing, supplies	Y	\$177,994
77	ResonanceDx	diagnostics	Carlos Moreno	Pathology & Laboratory Med	IB	9/19/18	\$49,994	manufacturing, market analysis	Y	
77	ResonanceDx	diagnostics	Carlos Moreno	Pathology & Laboratory Med	IIA	2/8/21	\$50,000	refine prototype device and improve software	Y	
77	ResonanceDx	diagnostics	Carlos Moreno	Pathology & Laboratory Med	IIB	5/12/21	\$50,000	finalize designs for scalable manufacture of reader and test devices	Y	
78	Sanguina (formerly HemoHome Diagnostics)	diagnostics	Wilbur Lam	Hematology & Oncology	IA	7/20/12	\$25,000	clinical validation	Y	\$205,000
78	Sanguina (formerly HemoHome Diagnostics)	diagnostics	Wilbur Lam	Hematology & Oncology	IB	2/19/13	\$13,000		Y	
78	Sanguina (formerly HemoHome Diagnostics)	diagnostics	Wilbur Lam	Hematology & Oncology	IC	3/6/14	\$25,000	FDA package	Y	
78	Sanguina (formerly HemoHome Diagnostics)	diagnostics	Wilbur Lam	Hematology & Oncology	IIA	3/29/16	\$81,000	consultants, salary, and supplies	Y	
78	Sanguina (formerly HemoHome Diagnostics)	diagnostics	Wilbur Lam	Hematology & Oncology	IIB	5/18/17	\$61,000	clinical studies, validation, formulation	Y	
79	Sequegenics (formerly HLA)	sequencing software	Eric Hunter/Dario Dileria	Yerkes	IA	3/10/16	\$47,460	market analysis, business model	Y	\$194,950
79	Sequegenics (formerly HLA)	sequencing software	Eric Hunter/Dario Dileria	Yerkes	IB	3/8/17	\$64,990	consultants (business strategy and IT)	Y	
79	Sequegenics (formerly HLA)	sequencing software	Eric Hunter/Dario Dileria	Yerkes	IC	3/26/19	\$32,500	front end development	Y	
79	Sequegenics (formerly HLA)	sequencing software	Eric Hunter/Dario Dileria	Yerkes	IIA	9/28/20	\$50,000	build a human genome database	Y	
80	Sickle Cell Anemia	drug development/therapeutics	Eric J. Sorscher and Wook Joon	Pediatrics	IA	12/14/20	\$25,000	sequaleae of sickle cell anemia	Y	\$25,000
81	Sophia Bioscience	drug discovery	John Petros	Urology	IIB	2/6/17	\$59,170	pre-clinical xenograft studies, efficacy studies	Y	\$59,170
82	Spectropath	medical device	Shuming Nie	Biomedical Engineering	IA	2/2/10	\$25,000	market research	Y	\$260,000
82	Spectropath	medical device	Shuming Nie	Biomedical Engineering	IB	7/21/10	\$25,000	in vivo studies	Y	
82	Spectropath	medical device	Shuming Nie	Biomedical Engineering	BIO/Plan	8/19/10	\$10,000	business plan	Y	
82	Spectropath	medical device	Shuming Nie	Biomedical Engineering	IIA	2/21/11	\$50,000	company infrastructure	Y	
82	Spectropath	medical device	Shuming Nie	Biomedical Engineering	IIB	8/24/11	\$50,000	product development	Y	
82	Spectropath	medical device	Shuming Nie	Biomedical Engineering	IIIA	4/24/12	\$100,000		Y	
83	Syntermed	Imaging software	Ernest Garcia	Radiology	Industry Partner	3/29/07	\$75,000	product reconstruction	Y	\$110,000
83	Syntermed	Imaging software	Ernest Garcia	Radiology	Industry Partner	3/27/09	\$35,000	prototyping	Y	
84	Targeted Delivery of Antibiotics	drug delivery	W. Robert Taylor	Biomedical Engineering	IA	2/22/17	\$24,643	efficacy studies, PK/PD data	Y	\$24,643
85	Targeted Prostate Cancer Therapeutics	drug discovery	John Petros	Urology	IB	1/15/13	\$22,400	efficacy studies in mouse model	Y	\$22,400
86	Tendonova (formerly Ultrasurgical)	medical device	Kenneth Mautner	Orthopedics	IA	11/23/15	\$49,250	market analysis, prototyping, product development	Y	\$197,894
86	Tendonova (formerly Ultrasurgical)	medical device	Kenneth Mautner	Orthopedics	IB	8/1/17	\$43,644	manufacturing, validation, design	Y	
86	Tendonova (formerly Ultrasurgical)	medical device	Shawna Khouri	Biomedical Engineering	IIA	3/18/19	\$36,000	design freeze, QMS system implementation	Y	
86	Tendonova (formerly Ultrasurgical)	medical device	Shawna Khouri	BME	IIB	9/12/19	\$69,000	prototype manufacturing & testing	Y	
87	Therapevo Pharmaceuticals	drug development	William Wuest	Chemistry	IA	9/19/18	\$70,600	develop small molecule library	Y	\$70,600
88	Velocity Medical Solutions	imaging software	Timothy Fox	Radiation Oncology	I A & B	12/13/05	\$50,000	regulatory due diligence	Y	\$425,000
88	Velocity Medical Solutions	imaging software	Timothy Fox	Radiation Oncology	IIA	9/8/06	\$50,000	prototyping & validation	Y	
88	Velocity Medical Solutions	imaging software	Timothy Fox	Radiation Oncology	IC	12/15/06	\$25,000	patent support	Y	
88	Velocity Medical Solutions	imaging software	Timothy Fox	Radiation Oncology	IIB	1/2/07	\$50,000	product development & marketing	Y	
88	Velocity Medical Solutions	imaging software	Timothy Fox	Radiation Oncology	IIIA	7/20/07	\$100,000		Y	
88	Velocity Medical Solutions	imaging software	Timothy Fox	Radiation Oncology	IIIB	12/12/08	\$150,000		Y	
89	πCIT	computer generated customized therapy plan	Nicki Panoskaltis	Hematology & Medical Oncology	IA	6/28/21	\$25,292	algorithm adaptation to create personalized treatment in pediatric cancer patients	Y	\$25,292
90	3D Ultrasound Products	software	Baowei Fei	Radiology	IA	2/19/13	\$10,000	business feasibility	N	\$10,000
91	3Ti (Transfusion & Transplantation Technologies, Inc.)	medical device	John Roback	Pathology	Industry Partner	3/28/07	\$60,000	test development	N	\$160,000
91	3Ti (Transfusion & Transplantation Technologies, Inc.)	medical device	John Roback	Pathology	IIIA	7/1/07	\$100,000	prototyping	N	

92	Aggregating Outliers	web-based software	Jorge Juncos	Neurology	IA	9/26/13	\$25,000	prototyping	N	\$25,000
93	Altiris (formerly Metastatix)	drug discovery	Dennis Liotta	Chemistry	IIA	3/25/05	\$50,000	compound selection	N	\$450,000
93	Altiris (formerly Metastatix)	drug discovery	Dennis Liotta	Chemistry	IIB	8/15/05	\$50,000	pre-clinical studies	N	
93	Altiris (formerly Metastatix)	drug discovery	Dennis Liotta	Chemistry	Industry Partne	3/24/07	\$100,000	compound screening	N	
93	Altiris (formerly Metastatix)	drug discovery	Dennis Liotta	Chemistry	IIIA	1/28/10	\$100,000	lead optimization	N	
93	Altiris (formerly Metastatix)	drug discovery	Dennis Liotta	Chemistry	IIIB	12/14/10	\$150,000		N	
94	Aviabiotic (formerly Chicken Probiotic)	agricultural	Ichiro Matsumura	Biochemistry	IA	2/9/19	\$30,000	plasmid generation	N	\$50,000
94	Aviabiotic (formerly Chicken Probiotic)	agricultural	Ichiro Matsumura	Biochemistry	IB	3/18/20	\$20,000	expression system prototyping	N	
95	AxoTect	drug discovery	Jonathan Glass	Neurology	IIA	11/4/05	\$8,000	pre-clinical studies	N	\$45,500
95	AxoTect	drug discovery	Jonathan Glass	Neurology	Industry Partne	3/27/09	\$37,500	dosing studies	N	
96	Biocertainty	biosafety training	Sean Kaufman	Epidemiology	IA	7/11/11	\$4,000	opportunity analysis	N	\$4,000
97	BioSequent	vascular grafts	Elliot Chaikof	Vascular Surgery	IA	2/26/07	\$15,000	prototyping	N	\$50,000
97	BioSequent	vascular grafts	Elliot Chaikof	Vascular Surgery	IB	3/14/08	\$35,000	prototyping & testing	N	
98	Cardiac Clinical Management System	web-based record keeping system	Karim Khan	Cardiology	IA	10/11/12	\$25,000	prototyping and testing	N	\$25,000
99	Cardiovascular Prevention Diagnostics	diagnostic biomarkers	Anh Ngoc Le	Medicine	IIA	10/27/06	\$50,000	prototyping	N	\$100,000
99	Cardiovascular Prevention Diagnostics	diagnostic biomarkers	Anh Ngoc Le	Medicine	IIB	12/15/06	\$50,000	clinical validation	N	
100	Cell Precision	medical device	W. Robert Taylor	Cardiology	IA	2/21/12	\$25,000	prototyping	N	\$35,000
100	Cell Precision	medical device	W. Robert Taylor	Cardiology	IB	10/11/12	\$10,000	final prototype	N	
101	Chronic Heart Failure Monitoring System	web-based system	Colleen Diiorio	Behavioral Science & Health, S	IA	9/8/10	\$25,000	market research & business model	N	\$25,000
102	Clear-Free Defibrillator	medical device	Michael Lloyd	Cardiology	IA	7/28/08	\$25,000	prototyping	N	\$25,000
103	CorSynergy	medical device	Thomas Vassiliades	Cardiothoracic Surgery	I A & B	12/13/05	\$42,000	prototyping	N	\$142,000
103	CorSynergy	medical device	Thomas Vassiliades	Cardiothoracic Surgery	IIA	9/8/06	\$50,000	prototyping	N	
103	CorSynergy	medical device	Thomas Vassiliades	Cardiothoracic Surgery	IIB	12/15/06	\$50,000	animal studies	N	
104	Dengue Virus	drug discovery	Abel De La Rosa / George Painl	DRIVE	IA	9/4/14	\$50,000	therapeutic optimization	N	\$94,000
104	Dengue Virus	drug discovery	Abel De La Rosa / George Painl	DRIVE	IB	11/23/15	\$44,000	pre-clinical testing, market analysis	N	
105	DiagNano	diagnostics	Shuming Nie	Biomedical Engineering	IA	9/25/08	\$25,000	prototyping	N	\$60,000
105	DiagNano	diagnostics	Shuming Nie	Biomedical Engineering	IB	2/27/09	\$25,000		N	
105	DiagNano	diagnostics	Shuming Nie	Biomedical Engineering	BIO/Plan	10/10/11	\$10,000	business plan	N	
106	Effigene Pharmaceuticals	drug discovery & research tools	Peng Jin	Human Genetics	Phase 0	3/20/08	\$10,000	e-commerce website	N	\$85,000
106	Effigene Pharmaceuticals	drug discovery & research tools	Peng Jin	Human Genetics	IA	9/25/08	\$25,000	structure optimization	N	
106	Effigene Pharmaceuticals	drug discovery & research tools	Peng Jin	Human Genetics	IB	2/27/09	\$25,000	structure optimization	N	
106	Effigene Pharmaceuticals	drug discovery & research tools	Peng Jin	Human Genetics	IC	10/26/09	\$25,000	structure optimization	N	
107	Fuzayo	web-based business courses for medical profes	Gary Bernstein	Surgery	IA	8/4/10	\$25,000	prototyping	N	\$25,000
108	G2 EcoSolutions	web-based consulting	John Notarantonio	Information Technology Division	IA	1/11/08	\$25,000	business plan	N	\$25,000
109	G2Bio	diagnostics	Mark Bousyk	Human Genetics	IA	2/27/09	\$25,000	commercial assessment	N	\$25,000
110	GlycArray	research reagents and services	Richard Cummings	Biochemistry	IA	1/7/13	\$25,000	market research & business models	N	\$25,000
111	Gold Complexes	drug discovery	Georgia Chen	Hematology/Oncology	IA	2/21/11	\$25,000	POP data	N	\$25,000
112	ImmunoMetrix	diagnostics	Jennifer Gooch & Allan Kirk	Nephrology, Surgery	IA	11/20/08	\$25,000	prototyping	N	\$200,000
112	ImmunoMetrix	diagnostics	Jennifer Gooch & Allan Kirk	Nephrology, Surgery	IB	2/27/09	\$25,000	testing	N	
112	ImmunoMetrix	diagnostics	Jennifer Gooch & Allan Kirk	Nephrology, Surgery	IC	7/20/12	\$150,000	transplant-derived samples	N	
113	InTailor Surgical	medical device	Edward Lin	Surgery	IA	9/4/14	\$42,400	efficacy in animal model	N	\$42,400
114	Kalman NewCo	drug discovery	Daniel Kalman	Pathology	Phase 0	1/2/07	\$10,000	market analysis	N	\$10,000
115	Ketal Biomedical	drug delivery	Michael Davis	Biomedical Engineering	IA (to GT)	7/29/09	\$25,000	animal data	N	\$118,000
115	Ketal Biomedical	drug delivery	Michael Davis	Biomedical Engineering	IB	7/29/09	\$25,000	animal data	N	
115	Ketal Biomedical	drug delivery	Michael Davis	Biomedical Engineering	IIA	8/19/10	\$50,000	prototyping	N	
115	Ketal Biomedical	drug delivery	Michael Davis	Biomedical Engineering	IIB	4/4/11	\$18,000	salary support	N	
116	Lukari	medical device	Jeremy Ackerman	Emergency Medicine	IA (to GT)	11/18/11	\$25,000	prototyping	N	\$50,000
116	Lukari	medical device	Jeremy Ackerman	Emergency Medicine	IB	10/11/12	\$25,000	product development	N	
117	NanoVici	drug discovery	Shuming Nie	Biomedical Engineering	IA & IB	12/13/05	\$50,000	toxicity studies	N	\$100,000
117	NanoVici	drug discovery	Shuming Nie	Biomedical Engineering	IIA	9/8/06	\$50,000	animal studies	N	
118	Nox2 Inhibitors for Chronic Inflammatory	drug discovery	David Lambeth	Pathology	IA & IB	8/8/12	\$50,000	in vitro safety & efficacy	N	\$100,000
118	Nox2 Inhibitors for Chronic Inflammatory	drug discovery	David Lambeth	Pathology	IIB	2/19/13	\$50,000	optimal dose, mouse asthma model	N	
119	Ontogenesys	biomaterials	Elliot Chaikof	Vascular Surgery	IA	8/31/09	\$13,000	market research	N	\$65,000
119	Ontogenesys	biomaterials	Elliot Chaikof	Vascular Surgery	IB	10/26/09	\$37,000	cost of scaling-up the production	N	
120	ProneuRx	drug discovery	Dennis Liotta	Chemistry	BIO/Plan	6/1/08	\$15,000	business plan	N	
121	Reperfusion Therapeutics	medical device	Jake Vinten-Johansen	Cardiothoracic Surgery	IA	8/29/05	\$30,000	prototyping	N	\$50,000
121	Reperfusion Therapeutics	medical device	Jake Vinten-Johansen	Cardiothoracic Surgery	IB	9/8/06	\$20,000	pig studies	N	
122	RSV Newco	drug discovery	Abel De La Rosa / Michael Nac	Emory Institute of Drug Discov	IA	9/4/14	\$50,000	therapeutic optimization	N	\$50,000
123	Scintigra	diagnostics	Mark Goodman	Radiology	IIA	11/20/08	\$50,000	human studies on fluorine-18 labeled FACPC	N	\$113,000

123 Scintigra	diagnostics	Mark Goodman	Radiology	IIB	7/29/09	\$43,000	business plan	N	
123 Scintigra	diagnostics	Mark Goodman	Radiology	BIO/Plan	8/31/09	\$20,000	clinical validation	N	
124 SciTribes	online network for scientists	Martin Moore	Pediatrics	IA	2/21/11	\$25,000	static website	N	\$25,000
125 Silagen	drug discovery	M. Neale Weitzmann & George	Endocrinology	IA	7/11/11	\$25,000	in vitro toxicity	N	\$60,000
125 Silagen	drug discovery	M. Neale Weitzmann & George	Endocrinology	BIO/Plan	10/12/11	\$10,000	business development plan	N	
125 Silagen	drug discovery	M. Neale Weitzmann & George	Endocrinology	IB	2/21/12	\$25,000	scale-up synthesis	N	
126 SkelRegen	drug discovery	Scott Boden	Orthopedics	IA	10/10/11	\$25,000	dose response studies	N	\$25,000
127 Somerset Research Group	medical device	John Scharf and James Cooke	Anesthesiology	IA	9/8/06	\$25,000	2nd generation prototype	N	\$50,000
127 Somerset Research Group	medical device	John Scharf and James Cooke	Anesthesiology	IB	12/15/06	\$25,000	10-patient trial	N	
128 Somnolytics	drug discovery	David Rye	Neurology	IA	2/2/10	\$25,000	POP data	N	\$25,000
129 SPECT-Guided CRT Technology	software	Ji Chen	Radiology	IA	12/18/12	\$25,000	2nd generation prototype	N	\$50,000
129 SPECT-Guided CRT Technology	software	Ji Chen	Radiology	IB	9/26/13	\$25,000	prototype testing	N	
130 Surgical Discharge Model	software	John Sweeney	Surgery	IA	12/18/12	\$25,000	adoption & integration	N	\$25,000
131 SynBioX	research tools	David Lynn	Chemistry	Phase 0	1/11/08	\$10,000	business plan	N	\$75,000
131 SynBioX	research tools	David Lynn	Chemistry	BIO/Plan	8/29/05	\$15,000	business plan	N	
131 SynBioX	research tools	David Lynn	Chemistry	I A & B	8/29/05	\$50,000	company formation	N	
132 SynP4	drug discovery	Don Stein & Dennis Liotta	Emergency Medicine, Chemist	IA	3/6/14	\$75,000	POP animal studies	N	\$75,000
133 TransTK Co	medical device	Kenneth Brigham	Pulmonology	Phase 0	1/18/06	\$10,000	niche analysis	N	\$10,000
134 Triptcor	drug discovery	Dennis Liotta	Chemistry	BIO/Plan	7/16/07	\$25,000	toxicity studies	N	\$25,000
135 Voxel Engineers	software	Marijn Brummer	Pediatrics	IA	8/4/10	\$17,500	market analysis	N	\$17,500
136 Wireless ECG	medical device	David Wright	Emergency Medicine	Phase 0	5/9/07	\$3,500	market analysis	N	\$3,500
137 Zetra Biologicals	vaccine discovery	Richard Compans	Microbiology & Immunology	IA	2/26/07	\$25,000	business plan & SBIR submission,	N	\$26,000
137 Zetra Biologicals	vaccine discovery	Richard Compans	Microbiology & Immunology	IB	3/14/08	\$1,000	fund raising	N	
138 Zirus	drug discovery	Dennis Liotta	Chemistry	IIB	8/31/09	\$50,000	target discovery	N	\$100,000
138 Zirus	drug discovery	Dennis Liotta	Chemistry	IIB	1/12/10	\$50,000	drug screening	N	

Total \$
\$15,090,548